{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:12:23Z","timestamp":1778825543269,"version":"3.51.4"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2026.1870909","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:36Z","timestamp":1778823816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Role of gamma delta T cells in cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Kawaljit","family":"Kaur","sequence":"first","affiliation":[{"name":"ImmuneLink, LLC","place":["San Diego, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1543454","article-title":"Uncovering the mysteries of human gamma delta T cells: from origins to novel therapeutics","volume":"16","author":"Bia\u0142y","year":"2025","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/322145a0","article-title":"Identification of a putative second T-cell receptor","volume":"322","author":"Brenner","year":"1986","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/322179a0","article-title":"A functional T3 molecule associated with a novel heterodimer on the surface of immature human thymocytes","volume":"322","author":"Bank","year":"1986","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/330572a0","article-title":"Peptide sequences of T-cell receptor delta and gamma chains are identical to predicted X and gamma proteins","volume":"330","author":"Born","year":"1987","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00366","article-title":"Insights into the relationship between Toll Like Receptors and Gamma Delta T Cell Responses","volume":"5","author":"Dar","year":"2014","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.101","article-title":"\u03b3\u03b4 T cells in homeostasis and host defence of epithelial barrier tissues","volume":"17","author":"Nielsen","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","article-title":"Human gamma delta T cells: Evolution and ligand recognition","volume":"296","author":"Adams","year":"2015","journal-title":"Cell Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(02)00850-1","article-title":"Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells","volume":"144","author":"von Lilienfeld-Toal","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01892-z","article-title":"V\u03b39V\u03b42 T cells recognize butyrophilin 2A1 and 3A1 heteromers","volume":"25","author":"Fulford","year":"2024","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00657","article-title":"Molecules and mechanisms implicated in the peculiar antigenic activation process of human V\u03b39V\u03b42 T cells","volume":"5","author":"Harly","year":"2014","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928441","article-title":"Role of V\u03b39v\u03b42 T lymphocytes in infectious diseases","volume":"13","author":"Gay","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41598-024-51794-1","article-title":"Human V\u03b39V\u03b42 T cell expansion and their cytotoxic responses against cholangiocarcinoma","volume":"14","author":"Sawaisorn","year":"2024","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.02.002","article-title":"Human V\u03b43(+) \u03b3\u03b4 T cells induce maturation and IgM secretion by B cells","volume":"196","author":"Petrasca","year":"2018","journal-title":"Immunol Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110288118","article-title":"Recognition of the antigen-presenting molecule MR1 by a V\u03b43+ \u03b3\u03b4 T cell receptor","volume":"118","author":"Rice","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1282758","article-title":"Gamma\/delta T cells as cellular vehicles for anti-tumor immunity","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00798-x","article-title":"\u03b3\u03b4 T cells as critical anti-tumor immune effectors","volume":"5","author":"Arias-Badia","year":"2024","journal-title":"Nat Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1562188","article-title":"\u03b3\u03b4T cells, a key subset of T cell for cancer immunotherapy","volume":"16","author":"Lv","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071063","article-title":"\u03b3\u03b4 T cells: game changers in immune cell therapy for cancer","volume":"17","author":"Subhi-Issa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100177","article-title":"Human \u03b3\u03b4 T cells in the tumor microenvironment: Key insights for advancing cancer immunotherapy","volume":"48","author":"Park","year":"2025","journal-title":"Molecules Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-025-00762-6","article-title":"Gamma delta T cells and their immunotherapeutic potential in cancer","volume":"13","author":"Cieslak","year":"2025","journal-title":"biomark Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of \u03b3\u03b4 T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1480191","article-title":"Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments","volume":"11","author":"Luo","year":"2024","journal-title":"Front Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451070","article-title":"Pro- and antitumorigenic functions of \u03b3\u03b4 T cells","volume":"54","author":"Fiala","year":"2024","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177143","article-title":"Advancements in gene therapy for human diseases: Trend of current clinical trials","volume":"986","author":"Delshad","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-443-21766-1.00002-3","article-title":"Chapter 5 - \u03b3\u03b4 T cells for cancer immunotherapy: A 2024 comprehensive systematic review of clinical trials","volume-title":"\u03b3\u03b4T cell cancer immunotherapy","author":"Barisa","year":"2025"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241284863","article-title":"Research progress of \u03b3\u03b4T cells in tumor immunotherapy","volume":"31","author":"Li","year":"2024","journal-title":"Cancer Control"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1282758","article-title":"Gamma\/delta T cells as cellular vehicles for anti-tumor immunity","volume":"14","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic Malignancies","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1182\/blood-2023-187058","article-title":"Phase I trial of allogeneic donor gamma delta T cell infusion post-hematopoietic cell transplantation, an interim safety report","volume":"142","author":"Bejanyan","year":"2023","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1182\/blood-2024-202363","article-title":"Phase I trial of ex vivo expanded donor gamma delta T cell immunotherapy to prevent acute myeloid leukemia relapse after allogeneic transplantation","volume":"144","author":"Bejanyan","year":"2024","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: Past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1185564","article-title":"An optimized cultivation method for future in vivo application of \u03b3\u03b4 T cells","volume":"14","author":"Bold","year":"2023","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200185","article-title":"Cutting edge: Bispecific \u03b3\u03b4 T cell engager containing heterodimeric BTN2A1 and BTN3A1 promotes targeted activation of V\u03b39V\u03b42(+) T cells in the presence of costimulation by CD28 or NKG2D","volume":"209","author":"Lai","year":"2022","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350773","article-title":"Camelid-derived Tcell engagers harnessing human \u03b3\u03b4 T cells as promising antitumor immunotherapeutic agents","volume":"54","author":"Boutin","year":"2024","journal-title":"Eur J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.1038\/s41467-024-53839-5","article-title":"A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T cell proliferation and anti-tumor immunity in mice","volume":"15","author":"Mebrahtu","year":"2024","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360237","article-title":"Advancements in \u03b3\u03b4T cell engineering: paving the way for enhanced cancer immunotherapy","volume":"15","author":"Yuan","year":"2024","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2024","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.07.001","article-title":"Prospects for chimeric antigen\u00a0receptor (CAR) \u03b3\u03b4 T cells: A potential game changer for adoptive T cell cancer immunotherapy","volume":"380","author":"Mirzaei","year":"2016","journal-title":"Cancer Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063154","article-title":"Preclinical evaluation of CAR T cell function: In vitro and in vivo models","volume":"23","author":"Si","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101241","article-title":"Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological Malignancies","volume":"68","author":"Arunachalam","year":"2024","journal-title":"Blood Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02401-0","article-title":"Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy","volume":"68","author":"Spear","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2021.11.018","article-title":"The power and the promise of CRISPR\/Cas9 genome editing for clinical application with gene therapy","volume":"40","author":"Guo","year":"2022","journal-title":"J Adv Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1492","article-title":"Effective \u03b3\u03b4 T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy","volume":"13","author":"Revesz","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202100035","article-title":"Engineering strategies for immunomodulatory cytokine therapies - challenges and clinical progress","volume":"4","author":"Pires","year":"2021","journal-title":"Adv Ther (Weinh)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114840","article-title":"Engineering cells for precision drug delivery: New advances, clinical translation, and emerging strategies","volume":"197","author":"Chao","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12951-020-00629-y","article-title":"Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges","volume":"18","author":"Jin","year":"2020","journal-title":"J Nanobiotechnol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00847-2","article-title":"Advancing engineering design strategies for targeted cancer nanomedicine","volume":"25","author":"Gomerdinger","year":"2025","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:39Z","timestamp":1778823819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1870909"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1870909","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1870909"}}